Melphalan Transport in Human Cancer Cells
Author Information
Author(s): B.C. Millar, J.A. Maitland, J.L. Millar, J.B.G. Bell
Primary Institution: Institute of Cancer Research
Hypothesis
The study investigates the role of the BCH-sensitive transport system in human lymphoid tumor cell lines compared to normal human bone marrow progenitors.
Conclusion
The study found that the BCH-sensitive transport system does not significantly affect melphalan toxicity in human malignant lymphoid cells.
Supporting Evidence
- BCH reduced melphalan incorporation by approximately 50% into mouse MIT 1 cells.
- BCH did not affect melphalan incorporation or toxicity in normal human bone marrow cells.
- Human malignant lymphoid cell lines showed minimal decrease in melphalan uptake in the presence of BCH.
Takeaway
This study looked at how a cancer drug called melphalan gets into cancer cells and found that it works differently in human cells than in mouse cells.
Methodology
The study used asynchronous cultures of various human and mouse cell lines and measured melphalan uptake and toxicity under different conditions.
Limitations
The study's findings may not apply to all human cancers, and further research is needed to explore melphalan transport at lower concentrations of BCH.
Participant Demographics
The study involved human malignant lymphoid cell lines and normal human bone marrow progenitors.
Want to read the original?
Access the complete publication on the publisher's website